Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Stichting Hemato-Oncologie voor Volwassenen Nederland: Clinical Trials & FDA Approval Profile

Stichting Hemato-Oncologie voor Volwassenen Nederland (Global / Institutional) sponsors 23 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 21 active protocols (10 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.3%
Median Closed Enrollment vs National (145 pts)91 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Stichting Hemato-Oncologie voor Volwassenen Nederland
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)23
Active Pipeline (Recruiting Now)21 (10)
Completed vs Stopped Early0 / 1 (4.3%)
Median Closed Actual Enrollment91 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06652438Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLPhase IIIRECRUITING
NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute MyePhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Stichting Hemato-Oncologie voor Volwassenen Nederland Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI